

Grifols renews its inclusion in the Dow Jones Sustainability Indices as one of the world's most sustainable companies

- *Grifols has been included in the Dow Jones Sustainability World Index (DJSI World) for the third consecutive year and the Dow Jones Sustainability Europe Index (DJSI Europe) for fourth straight year*
- *Grifols continues to rank among the top-scoring biotechnology companies, excelling in business ethics, human rights, innovation management, labor practice indicators, product quality and recall management, health outcome contribution and marketing practices*
- *This strong positioning in the DJSI reflects Grifols' standing as a sustainability leader, on the back of recent efforts to strengthen its longstanding corporate responsibility actions in diversity and inclusion, equality and climate change*

Barcelona, Spain - December 11, 2023 – Grifols, a leading manufacturer of plasma-derived medicines, has been named to the S&P Dow Jones Sustainability Indices (DJSI) for the fourth consecutive year, reflecting the company's ongoing commitment to environmental, social, and governance (ESG) leadership.

The Dow Jones Sustainability Index is comprised of global sustainability leaders identified by S&P Global via the Corporate Sustainability Assessment (CSA), an annual evaluation comparing companies across 61 industries via questionnaires to assess financially relevant sustainability criteria across economic, environmental, and social dimensions.

Over 13,000 companies were invited to participate in the CSA this year and the index represents the top 10% of the largest 2,500 companies in the S&P Global Broad Market Index. Grifols has been included in 2023 DJSI World and Europe for the third- and fourth-year running, respectively.

“We at Grifols are honored to be recognized once again in the Dow Jones Sustainability Index as one of the world's most sustainable companies. This prestigious acknowledgment reflects our longstanding commitment to prioritizing the health and safety of donors and patients, contributing meaningfully to society and the environment, and supporting our employees with integrity and transparency,” said **Raimon Grifols**, Chief Corporate Officer.

“Sustainability lies at the heart of our company and is a key priority in our 2030 agenda as we adapt to societal changes and continue to grow. Guided by our core values and a drive to demonstrate leadership in our industry, we strive to address the pressing global challenges of

GRIFOLS

climate, health, and equity. This excellent achievement is a testament to the dedication of Grifols' employees. As we look forward to the years ahead, we continue to work to uphold and exceed this standard of excellence, ensuring that sustainability remains a cornerstone of all our endeavors at Grifols", he added.

Grifols has set itself apart by achieving a top-tier position in the Biotechnology industry, comprising 372 companies, according to this year's Corporate Sustainability Assessment (CSA), as of November 24, 2023. This notable achievement is a testament to the company's considerable progress in key areas such as human rights, innovation management, labor practices, product quality, recall management, and health outcomes. Additionally, Grifols stands out in business ethics and marketing practices, further solidifying its reputation for ethical and sustainable business practices within the biotech sector.

For more information on Grifols' ESG initiatives and progress, please visit [Sustainability | Grifols](#) and read more about our commitment in [Integrated and Sustainability Annual Report](#).

Grifols Sustainability recognitions

Grifols has been included in the FTSE4Good Global, FTSE4Good Europe and FTSE4Good Ibex sustainability stock market indices since 2018, and on the Euronext Vigeo Europe 120 and Euronext Vigeo Eurozone 120 indices, based on the Vigeo Eiris assessment, since 2020. Grifols has additionally been recognized with the EcoVadis Gold Medal in 2023. Since 2021, Grifols has also been included in the Bloomberg Gender-Equality Index (GEI) in recognition of its commitment to addressing gender inequality. Forbes and Statista also recognize Grifols as one of the World's Top Companies for Women 2023.

INVESTORS:

Grifols Investors Relations & Sustainability
inversores@grifols.com - investors@grifols.com
sostenibilidad@grifols.com - sustainability@grifols.com
Tel. +34 93 571 02 21

MEDIA CONTACTS:

Grifols Press Office media@grifols.com / Tel. +34 93 571 00 02	
Spain Duomo Comunicación Tel.: +34 91 311 92 89 – +34 91 311 92 90 Raquel Lumbreras (M. +34 659 572 185) Raquel_lumbreras@duomocomunicacion.com Borja Gómez (M. +34 650 402 225) Borja_gomez@duomocomunicacion.com	International FGS Global Email: Grifols@fgsglobal.com Tel.: +44 20 7251 3801 Charles.Obrien@fgsglobal.com James.Gray@fgsglobal.com

GRIFOLS

About the Dow Jones Sustainability Index (DJSI)

The Dow Jones Sustainability Index (DJSI), jointly developed by S&P Dow Jones Index and RobecoSAM, are corporate sustainability evaluation indices for environmental, social and governance (ESG) investment that serve as a benchmark for investors who integrate sustainability considerations into their portfolios and look for best-in-class performance. The indices have achieved an iconic status as the global standard for measuring and advancing corporate ESG practices. More specifically, the DJSI World targets the top 10% of ESG performers which S&P Global considers key to generating long-term stakeholder value. To prepare the Dow Jones Sustainability Index, S&P Dow Jones applies a transparent, rules based constituent selection process based on companies' S&P Global Corporate Sustainability Assessment (CSA). The CSA consists of an extended questionnaire assessing both public and non-public data submitted by participating companies. This year, more than 10,000 publicly traded companies were invited to participate in the S&P Global CSA.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

In 2022, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information about Grifols, please visit www.grifols.com

